Fully automated high-performance liquid chromatography of ciprofloxacin with direct injection of plasma and Mueller-Hinton broth for pharmacokinetic/pharmacodynamic studies

Optimization of High-Performance Liquid Chromatographic Method Using Central Composite Design for the Simultaneous Estimation of Ciprofloxacin and Loteprednol

A simple, rapid, precise and accurate stability indicating high-performance liquid chromatographic (HPLC) method was developed for simultaneous quantification of Ciprofloxacin (CIP) and Loteprednol (LOT) along with their forced degradation products using central composite design (CCD) approach. CCD was prepared with three independent variables in a gradient HPLC method. In gradient program (GP) the ratio of phosphate buffer in the mobile phase was 70%, 75%, 80%, 85% and 90%, the pH of phosphate buffer was 2.6, 2.8, 3.0, 3.2 and 3.4, flow rate was 0.8, 0.9, 1.0, 1.1 and 1.2 mL/min. Resolution, tailing factor (CIP) and tailing factor (LOT) were selected as response factor. The effective separation of LOT and CIP was achieved on Phenomenex EVO-C18 column (4.6 mm × 250 mm × 5 μm particle size) opting gradient mode of elution. The mobile phase composed of 10 mM Phosphate buffer pH 3.2 with ortho-phosphoric acid and the organic phase composed of mixture of acetonitrile and methanol in 50:50% v/v with flow rate of 1 mL/min and diode array detection at 258 nm. The optimized variables found were flow rate of 1.0 mL/min, ratio of phosphate buffer in GP 80% at pH 3.0. The method was validated as per ICH guidelines and applied for analysis of stability samples.

Evaluation of physicochemical properties as supporting information on quality control of raw materials and veterinary pharmaceutical formulations

This study aimed to show that the physicochemical proprieties obtained by Fourier transform infrared spectroscopy (FTIR), thermogravimetry (TG), and scanning electronic microscopy (SEM) can be useful tools for evaluating the quality of active pharmaceutical ingredients (APIs) and pharmaceutical products. In addition, a simple, sensitive, and efficient method employing HPLC-DAD was developed for simultaneous determination of lidocaine (LID), ciprofloxacin (CFX) and enrofloxacin (EFX) in raw materials and in veterinary pharmaceutical formulations. Compounds were separated using a Gemini C₁₈ (250 mm × 4.6 mm, 5 µm) Phenomenex^® column, at a temperature of 25 °C, with a mobile phase containing 10 mM of phosphoric acid (pH 3.29): acetonitrile (85.7:14.3, v/v) and a flow rate of 1.5 mL/min. Physicochemical characterization by TG, FTIR, and SEM of raw materials of LID, CFX, and EFX provided information useful for the evaluation, differentiation, and qualification of raw materials. Finally, the HPLC method was proved to be useful for evaluation of raw material and finished products, besides satisfying the need for an analytical method that allows simultaneous determination of EFX, CFX, and LID, which can also be extended to other matrices and applications.

•

FTIR, TGA, and SEM are useful tools for the evaluation of the quality of APIs.

•

A RP-HPLC method was developed and validated for the determination of LID, CFX, EFX.

•

The proposed RP-HPLC method showed precise and accurate results in quality control.

•

This method can be applied to the analysis of veterinary pharmaceutical products.

Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition

Clinical pharmacokinetic studies of ciprofloxacin require accurate and precise measurement of plasma drug concentrations. We describe a rapid, selective and sensitive HPLC method coupled with fluorescence detection for determination of ciprofloxacin in human plasma. Internal standard (IS; sarafloxacin) was added to plasma aliquots (200 μL) prior to protein precipitation with acetonitrile. Ciprofloxacin and IS were eluted on a Synergi Max-RP analytical column (150 mm×4.6 mm i.d., 5 μm particle size) maintained at 40°C. The mobile phase comprised a mixture of aqueous orthophosphoric acid (0.025 M)/methanol/acetonitrile (75/13/12%, v/v/v); the pH was adjusted to 3.0 with triethylamine. A fluorescence detector (excitation/emission wavelength of 278/450 nm) was used. Retention times for ciprofloxacin and IS were approximately 3.6 and 7.0 min, respectively. Calibration curves of ciprofloxacin were linear over the concentration range of 0.02-4 μg/mL, with correlation coefficients (r(2))≥0.998. Intra- and inter-assay relative standard deviations (SD) were <8.0% and accuracy values ranged from 93% to 105% for quality control samples (0.2, 1.8 and 3.6 μg/mL). The mean (SD) extraction recoveries for ciprofloxacin from spiked plasma at 0.08, 1.8 and 3.6 μg/mL were 72.8±12.5% (n=5), 83.5±5.2% and 77.7±2.0%, respectively (n=8 in both cases). The recovery for IS was 94.5±7.9% (n=15). The limits of detection and quantification were 10 ng/mL and 20 ng/mL, respectively. Ciprofloxacin was stable in plasma for at least one month when stored at -15°C to -25°C and -70°C to -90°C. This method was successfully applied to measure plasma ciprofloxacin concentrations in a population pharmacokinetics study of ciprofloxacin in malnourished children.

Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection

The plasma kinetics of ciprofloxacin (CF) were investigated in the eels after administration by oral gavage and bath treatment. Plasma concentrations of CF were determined by high-performance liquid chromatography with fluorescence detection. The mean concentration time data after oral gavage of a single dose (10.0 mg/kg CF) and after bath treatment by exposure (10 microg/ml CF) to medicated water for 48 h were both best fitted by a one-compartment model. After oral gavage in eels, the half-time of absorption (T1/2Ka) was 0.10 h, the half-time of elimination (T1/2Ke) was 51.87 h, and the maximum plasma concentration (Cmax) was 0.4552 microg/ml at Tmax 0.88 h. After bath treatment, the (T1/2Ka) was 0.02 h, the (T1/2Ke) was 15.46 h, and the Cmax was 0.1175 microg/mL at Tmax 0.22 h.

High-performance liquid chromatographic determination of ciprofloxacin in plasma samples

A new bioanalytical high-performance liquid chromatographic (HPLC) method for the determination of ciprofloxacin with norfloxacin as an internal standard was developed and validated for plasma samples. Norfloxacin is structural homologue of ciprofloxacin and exhibits similar retention properties. The quality of respective peak separation is strongly influenced by amphoteric character of ciprofloxacin and norfloxacin as well. In previously published HPLC methods on conventional C18 reversed-phase [F. Belal, A.A. Al-Majed, A.M. Al-Obaid, Talanta 50 (1999) 765-786; G. Carlucci, J. Chromatogr. A 812 (1998) 343-367], ion pair reagents were added into the mobile phase to suppress peak tailing. In comparison with endcapped and high purity silica reversed-phase sorbent (Purospher RP-18e, Merck), which yielded symmetrical peaks, separation efficiency was further enhanced in our method. Gradient elution mode using acetonitrile and phosphate buffer pH 3 on the pentafluorophenylpropyl stationary phase (250-4.6 mm Discovery HS F5, 5 microm, Supelco) was carried out. The resolution of 4.1 for ciprofloxacin-norfloxacin peaks was achieved. Sample preparation by SPE C18 (Supelclean) with recovery 72% was performed. Fluorescence detection with lambda(excit)=280 nm, lambda(emis)=446 nm was used. After the validation, the bioanalytical HPLC method was applied to pharmacokinetic studies.

Determination of ciprofloxacin concentrations in human serum and urine by HPLC with ultraviolet and fluorescence detection

OBJECTIVE

To develop a simple and sensitive high performance liquid chromatography method for the determination of ciprofloxacin concentrations in human serum and urine.

METHOD

Serum proteins were removed by ultrafiltration through a filtering device after the addition of a displacing reagent. Urine samples were diluted with mobile phase prior to injection. Separation was achieved with a C18 reverse-phase column and using ultraviolet (UVD) and fluorescence detection (FD) for serum samples and UVD for urine samples.

RESULTS

The quantitation limits of the assay were 20 ng/ml (FD) and 100 ng/ml (UVD) in serum and 1 microg/ml in urine. The assay was successfully applied to a pharmacokinetic study of ciprofloxacin in healthy volunteers.

CONCLUSION

The method presented for ciprofloxacin assay in human serum and urine requires less sample clean up and is more sensitive than those reported in the literature.

Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model

A two-compartment in vitro pharmacokinetic-pharmacodynamic model, with full computer-controlled devices, was used to accurately simulate human plasma pharmacokinetic profiles after multidose oral regimens of ciprofloxacin (750 mg every 12 h) and moxifloxacin (400 mg every 24 h) during 48 h. Pharmacodynamics of these drugs was investigated against three quinolone-susceptible strains of Stenotrophomonas maltophilia (MICs of ciprofloxacin and moxifloxacin of 0.5 to 2 and 0.0625 to 0.5 microg/ml, respectively). The first dose of ciprofloxacin and moxifloxacin reduced the bacterial count by 1 and 2 log CFU/ml, respectively, prior to a bacterial regrowth that reached the plateau value of the growth control curve at 13 to 24 h versus 24 to 36 h and persisted despite repeated administration of both drugs. The surviving bacterial cells were quinolone-resistant mutants (2 to 128 times the MIC) that exhibited cross-resistance to unrelated antibiotics. Their antibiotic resistance probably resulted from the overproduction of different multidrug resistance efflux system(s). C(max)/MIC and area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC values were at least threefold higher for moxifloxacin than for ciprofloxacin. Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia. However, selection of resistant mutants by both fluoroquinolones, although delayed with moxifloxacin, emphasizes the need to use maximal dosages and combined therapy in the treatment of systemic S. maltophilia infections.

Atomic absorption spectroscopic, conductometric and colorimetric methods for determination of fluoroquinolone antibiotics using ammonium reineckate ion-pair complex formation

Three accurate, rapid and simple atomic absorption spectrometric, conductometric and colorimetric methods were developed for the determination of norfloxacin (NRF), ciprofloxacin (CIP), ofloxacin (OFL) and enrofloxacin (ENF). The proposed methods depend upon the reaction of ammonium reineckate with the studied drugs to form stable precipitate of ion-pair complexes, which was dissolved in acetone. The pink coloured complexes were determined either by AAS or colorimetrically at lambdmax 525 nm directly using the dissolved complex. Using conductometric titration, the studied drugs could be evaluated in 50% (v/v) acetone in the range 5.0-65, 4.0-48, 5.0-56 and 6.0-72 microg ml-1 of NRF, CPF, OFL and ENF, respectively. The optimizations of various experimental conditions were described. The results obtained showed good recoveries of 99.15 +/- 1.15, 99.30 +/- 1.40, 99.60 +/- 1.50, and 99.00 +/- 1.25% with relative standard deviations of 0.81, 1.06, 0.97, and 0.69% for NRF, CPF, OFL, and ENF, respectively. Applications of the proposed methods to representative pharmaceutical formulations are successfully presented.

Validation of an HPLC method for the determination of ciprofloxacin in human plasma

A simple HPLC method with fluorescence detection of ciprofloxacin in human plasma was developed and validated. After protein precipitation, chromatographic separation of ciprofloxacin in plasma was achieved at 35 degrees C with a C18 column and acetonitrile-phosphate mixture, pH 3, as mobile phase. Quantitative determination was performed by fluorimetry after excitation at 278 nm. The method was specific and validated with a limit of quantification of 41 ng/ml. The intra- and inter-day coefficients of variation were between 0.5 and 6.6% and accuracy between -2.02 and 7.04%. Ciprofloxacin was stable in plasma for 40 days at -20 degrees C and after three freezing-thawing cycles. The method has been applied in a bioequivalence study of two formulation of 500 mg ciprofloxacin.

Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation

A spectrophotometric method was described for the determination of the antibacterial quinolone derivatives, ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation with three different acceptors. Chloranilic acid (CL) was utilized for their determination, forming charge transfer complex with lambdamax 520 nm. The proposed method was applied for determination of Ciprocin tablets, Enroxil oral solution, Peflacin ampoules and Peflacin tablets, with mean percentage accuracies, 99.58+/-1.25,99.94+/-0.96,100.91+/-1.59 and 99.86+/-1.003. Also, tetracyanoethylene (TCNE) was utilized in the determination of the concerned compounds forming charge transfer complexes with maximum absorbances at lambdamax 335 nm for ciprofloxacin and at lambdamax 290 nm for both enrofloxacin and pefloxacin. The procedure was applied for determination of Ciprocin tablets, Enroxil 10% oral solution, Peflacine tablets and Peflacine ampoules with mean percentage accuracies 99.40+/-1.27,99.95+/-0.90,98.98+/-1.565 and 99.88+/-0.998, respectively. Also, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) was utilized for determination of pefloxacin forming charge transfer complex with maximum absorbance at lambdamax 460 nm. The procedure was applied for determination of peflacine tablets and peflacine ampoules with mean percentage accuracies 100.40+/-0.76 and 99.91+/-0.623, respectively. Statistical analysis of the obtained results showed no significant difference between the proposed method and other official and reported methods as evident from the t-test and variance ratio.

Determination of moxifloxacin in growth media by high-performance liquid chromatography

A direct injection high-performance liquid chromatographic method with column switching has been developed to determine moxifloxacin in Mueller-Hinton broth. A LiChrocart 4-4 pre-column filled with a LiChrospher 100 RP 18, 5 microm and a 150 x 4.6 mm I.D. column packed with a Supelcozil ABZ+ Plus were used and led to a retention time of 5.70 min. Fluorescence detection allowed one to reach a quantification limit of 0.05 microg/ml with a 100-microl sample size. The standard curves were linear from 0.05 to 3.2 microg/ml. Intra- and inter-day imprecisions within the linearity range were < or =4.76 and < or =5.75%, respectively. The mean relative errors for the same day and the day-to-day inaccuracies ranged from -2.93 to +4.50% and from -1.10 to +6.00%, respectively. The method was demonstrated to be useful for pharmacokinetic-pharmacodynamic studies of moxifloxacin in an in vitro model.

Column-switching high-performance liquid chromatographic assay for determination of asiaticoside in rat plasma and bile with ultraviolet absorbance detection

A column-switching high-performance liquid chromatography (HPLC) method is described for the determination of asiaticoside in rat plasma and bile using column-switching and ultraviolet (UV) absorbance detection. Plasma was simply deproteinated with acetonitrile prior to injection and bile was directly injected onto the HPLC system consisting of a clean-up column, a concentrating column, and an analytical column, which were connected with two six-port switching valves. Detection of asiaticoside was accurate and repeatable, with a limit of quantification of 0.125 microg/ml in plasma and 1 microg/ml in bile. The calibration curves were linear in a concentration range of 0.125-2.5 microg/ml and 1-20 microg/ml for asiaticoside in rat plasma and bile, respectively. This method has been successfully applied to determine the level of asiaticoside in rat plasma and bile samples from pharmacokinetics and biliary excretion studies.